further development of these product candidates would be conditioned , in part , on obtaining additional funding , collaborations or emergency use . our discovery and research programs include collaborations with various third parties and focus on developing therapeutics in rare , genetic , anti-bacterial , neuromuscular and central nervous system diseases amongst other diseases . we are exploring the application of our proprietary phosphorodiamidate morpholino oligomer ( “ pmo ” ) platform technology in various diseases . we believe we have developed proprietary state-of-the-art manufacturing and scale-up techniques that allow synthesis and purification of our product candidates to support clinical development as well as potential commercialization . we have entered into certain manufacturing and supply arrangements with third-party suppliers which will in part utilize these techniques to support production of certain of our product candidates and their components . we currently do not have any of our own internal mid-to-large scale manufacturing capabilities to support our product candidates . the basis of our novel rna-targeted therapeutics is the pmo . our next generation pmo-based chemistries include pmo-x ® , pmo plus ® and ppmo . pmo and pmo-based compounds are highly resistant to degradation by enzymes , potentially enabling robust and sustained biological activity . in contrast to other rna-targeted therapeutics , which are usually designed to down-regulate protein expression , our technologies are designed to selectively up-regulate or down-regulate protein expression , and more importantly , create novel proteins . pmo and pmo-based compounds have demonstrated inhibition of messenger rna ( “ mrna ” ) translation and alteration of pre-mrna splicing . pmo and pmo-based compounds have the potential to reduce off-target effects , such as the immune stimulation often observed with ribose-based rna technologies . we believe that our highly differentiated , novel , proprietary and innovative rna-targeted pmo-based platforms may represent a significant improvement over other rna-targeted technologies . in addition , pmo and pmo-based compounds are highly adaptable molecules : with minor structural modifications , they can potentially -40- be rapidly designed to target specific tissues , genetic sequences , or pathogens , and therefore , we believe they could potentially be applied to treat a broad spectrum of diseases . we have not generated any revenue from product sales to date and there can be no assurance that revenue from product sales will be achieved . even if we do achieve revenue from product sales , we are likely to continue to incur operating losses in the near term . as of december 31 , 2015 , we had approximately $ 204.0 million of cash , cash equivalents and investments , consisting of $ 80.3 million of cash and cash equivalents , $ 112.2 million of short-term investments and $ 11.5 million of restricted cash and investments . we believe that our balance of cash , cash equivalents and investments is sufficient to fund our current operational plan for at least the next twelve months . as of december 31 , 2014 , we had completed all development activities under the agreements with the dod . we are currently exploring possibilities for funding , collaboration and other avenues to support further development of these ebola , marburg and influenza product candidates . without funding from the u.s. government , we would likely curtail certain infectious disease research and development efforts , though we may pursue additional cash resources through public or private financings , seek additional government contracts and establish collaborations with or license our technology to other companies . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with government sponsored programs and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenue or profitable operations . summary and timeline of eteplirsen data disclosure in october 2010 , we announced results from a clinical trial of eteplirsen ( “ avi study 28 ” ) . data from this study were published in the lancet in july 2011. avi study 28 was a phase ib/iia open label , dose-ranging , clinical trial assessing the safety , tolerability , pharmacokinetics and exploratory efficacy of eteplirsen in ambulatory individuals with dmd . participants in avi study 28 were between the ages of five and 15 with errors in the gene coding for dystrophin , which were amenable to treatment by skipping exon 51. participants were dosed once per week for 12 weeks . a total of 19 participants were enrolled and these individuals were assigned to one of six dose cohorts of 0.5 , 1.0 , 2.0 , 4.0 , 10.0 or 20.0 mg/kg . of the 19 participants enrolled , 18 received at least ten of the 12 doses planned in this trial . after completion of dosing , participants were followed for an additional 14 weeks . muscle biopsies were taken before treatment and 17 participants had a second biopsy at week 14 , two weeks after administration of the final dose . the primary objective of the trial was to assess the safety of eteplirsen at these doses over the 26-week duration of the trial . secondary trial objectives included assessment of plasma pharmacokinetics , urinary elimination and exploratory endpoints evaluating biological activity and clinical performance . this trial was conducted by investigators in the united kingdom at the university college london institute of child health / great ormond street hospital in london and at the royal victoria infirmary in newcastle-upon-tyne . story_separator_special_tag these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from b aseline through week 144 in the itt population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , showed a 14.7 percent mean increase in mip and a 12.8 percent mean increase in mep . analyses of mip percent predicted ( mip adju sted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 93.9 percent at week 144 in mip percent predicted , and a mean change from 79.3 percent at baseline to 75.7 percent at week 144 in mep percent predicted . in addition , there was a mean increase in forced vital capacity ( “ fvc ” ) , a measure of lung volume , of 11.0 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 144 , with 1 01.3 percent at baseline and 90.9 percent at week 144. through 144 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there w ere no treatment-related hospitalizations or discontinuations . in january 2015 , we announced that at week 168 , the six patients in the mitt population in the 30 and 50 mg/kg eteplirsen cohorts who were able to perform the 6mwt experienced a decline of 76.7 meters , or about 19.5 percent , from baseline in walking ability . a statistically significant treatment benefit of 65.4 meters ( p < 0.017 ) was observed compared with the placebo/delayed-treatment cohort ( n=4 ) , which initiated treatment at week 25 following 24 weeks of placebo . this cohort , after experiencing a substantial decline of 68.4 meters from baseline to week 36 , demonstrated a decline of 73 meters in walking ability from week 36 through week 168 , the period from which meaningful levels of dystrophin were likely produced . these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from baseline through week 168 in the intent-to-treat population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , continued to show a 11.1 percent mean increase in mip and a 14.7 percent mean increase in mep . analyses of mip percent predicted ( mip adjusted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 89.5 percent at week 168 in mip percent predicted , and a mean change from 79.3 percent at baseline to 74.3 percent at week 168 in mep percent predicted . in addition , there was a mean increase in fvc , a measure of lung volume , of 11.6 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 168 , with 101.3 percent at baseline and 91.9 percent at week 168. through 168 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . in october 2015 , we announced additional clinical efficacy and safety data that demonstrated that ( i ) eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk ( as measured by the 6mwt ) at three years , compared with external controls , ( ii ) the fourth biopsy data confirmed the mechanism of action of eteplirsen , demonstrating exon skipping in all patients and dystrophin production in nearly all patients and ( iii ) at three years , the safety data remained consistent with prior results . in january 2016 , the fda made public our eteplirsen briefing document addendum ( the “ january 2016 addendum ” ) which disclosed that at four years , 10 out of 12 patients on eteplirsen remained ambulatory while 10 out of 13 untreated patients in the external control had lost ambulation ( one patient in the external control was still ambulatory at year 4 , while 2 patients in the external control were missing data at 4 years ) , a statistically significant difference . in addition , the january 2016 addendum disclosed a statistically significant advantage of 162 meters in the ability of study participants to walk ( as measured by the 6mwt ) at four years . key financial metrics revenue government research contract and grant revenue . in the periods presented in this report , substantially all of our revenues were derived from research and development contracts with and grants from the u.s. government . we recognize revenue from u.s. government research contracts and grants during the period in which the related expenses are incurred and present such revenues and related expenses on a gross basis in the consolidated financial statements . our government contracts are subject to government audits , which may result in catch-up adjustments . as of december 31 , 2014 , we had completed all development activities of our contracts with the u.s. government . the majority of the revenue under our u.s. government contracts was recognized as of december 31 , 2015 and only revenue for contract finalization , if any , is expected in the future . if a technology , right , product or service is separate and independent of our performance under other elements of an arrangement , we defer recognition of non-refundable up-front fees if we have continuing performance obligations when the technology , right , product or service conveyed in conjunction with the non-refundable fee has no utility to the

liquidity and capital resources the following table summarizes our financial condition for each of the periods indicated : replace_table_token_9_th for the year ended december 31 , 2015 , our principal sources of liquidity were from equity and debt financings . for the year ended december 31 , 2014 , our principal source of liquidity was from an equity financing . our principal uses of cash are research and development expenses , general and administrative expenses , capital expenditures and other working capital requirements . our future expenditures and capital requirements may be substantial and will depend on many factors , including but not limited to the following : · the timing and costs associated with commercialization of eteplirsen should marketing approval ever be granted ; · the timing and costs of building out our manufacturing capabilities ; · the timing of advanced payments related to our future inventory commitments ; · the timing and costs associated with our clinical trials and preclinical studies ; and · the costs of filing , prosecuting , defending and enforcing patent claims and our other intellectual property rights . our cash requirements are expected to continue to increase as we advance our research , development and commercialization programs and we expect to seek additional financing primarily from , but not limited to , the sale and issuance of equity , debt securities or the licensing or sale of our technology . we can not provide assurances that financing will be available when and as needed or that , if available , the financings will be on favorable or acceptable terms . if we are unable to obtain additional financing when and if we require , this would have a material adverse effect on our business and results of operations . to the extent we issue additional equity securities , our existing stockholders could experience substantial dilution . -51- cash flows the following table summarizes our cash flow activity for each of the periods indicated : replace_table_token_10_th operating activities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources the following table summarizes our financial condition for each of the periods indicated : replace_table_token_9_th for the year ended december 31 , 2015 , our principal sources of liquidity were from equity and debt financings . for the year ended december 31 , 2014 , our principal source of liquidity was from an equity financing . our principal uses of cash are research and development expenses , general and administrative expenses , capital expenditures and other working capital requirements . our future expenditures and capital requirements may be substantial and will depend on many factors , including but not limited to the following : · the timing and costs associated with commercialization of eteplirsen should marketing approval ever be granted ; · the timing and costs of building out our manufacturing capabilities ; · the timing of advanced payments related to our future inventory commitments ; · the timing and costs associated with our clinical trials and preclinical studies ; and · the costs of filing , prosecuting , defending and enforcing patent claims and our other intellectual property rights . our cash requirements are expected to continue to increase as we advance our research , development and commercialization programs and we expect to seek additional financing primarily from , but not limited to , the sale and issuance of equity , debt securities or the licensing or sale of our technology . we can not provide assurances that financing will be available when and as needed or that , if available , the financings will be on favorable or acceptable terms . if we are unable to obtain additional financing when and if we require , this would have a material adverse effect on our business and results of operations . to the extent we issue additional equity securities , our existing stockholders could experience substantial dilution . -51- cash flows the following table summarizes our cash flow activity for each of the periods indicated : replace_table_token_10_th operating activities .
```    
 Suspicious Activity Report : further development of these product candidates would be conditioned , in part , on obtaining additional funding , collaborations or emergency use . our discovery and research programs include collaborations with various third parties and focus on developing therapeutics in rare , genetic , anti-bacterial , neuromuscular and central nervous system diseases amongst other diseases . we are exploring the application of our proprietary phosphorodiamidate morpholino oligomer ( “ pmo ” ) platform technology in various diseases . we believe we have developed proprietary state-of-the-art manufacturing and scale-up techniques that allow synthesis and purification of our product candidates to support clinical development as well as potential commercialization . we have entered into certain manufacturing and supply arrangements with third-party suppliers which will in part utilize these techniques to support production of certain of our product candidates and their components . we currently do not have any of our own internal mid-to-large scale manufacturing capabilities to support our product candidates . the basis of our novel rna-targeted therapeutics is the pmo . our next generation pmo-based chemistries include pmo-x ® , pmo plus ® and ppmo . pmo and pmo-based compounds are highly resistant to degradation by enzymes , potentially enabling robust and sustained biological activity . in contrast to other rna-targeted therapeutics , which are usually designed to down-regulate protein expression , our technologies are designed to selectively up-regulate or down-regulate protein expression , and more importantly , create novel proteins . pmo and pmo-based compounds have demonstrated inhibition of messenger rna ( “ mrna ” ) translation and alteration of pre-mrna splicing . pmo and pmo-based compounds have the potential to reduce off-target effects , such as the immune stimulation often observed with ribose-based rna technologies . we believe that our highly differentiated , novel , proprietary and innovative rna-targeted pmo-based platforms may represent a significant improvement over other rna-targeted technologies . in addition , pmo and pmo-based compounds are highly adaptable molecules : with minor structural modifications , they can potentially -40- be rapidly designed to target specific tissues , genetic sequences , or pathogens , and therefore , we believe they could potentially be applied to treat a broad spectrum of diseases . we have not generated any revenue from product sales to date and there can be no assurance that revenue from product sales will be achieved . even if we do achieve revenue from product sales , we are likely to continue to incur operating losses in the near term . as of december 31 , 2015 , we had approximately $ 204.0 million of cash , cash equivalents and investments , consisting of $ 80.3 million of cash and cash equivalents , $ 112.2 million of short-term investments and $ 11.5 million of restricted cash and investments . we believe that our balance of cash , cash equivalents and investments is sufficient to fund our current operational plan for at least the next twelve months . as of december 31 , 2014 , we had completed all development activities under the agreements with the dod . we are currently exploring possibilities for funding , collaboration and other avenues to support further development of these ebola , marburg and influenza product candidates . without funding from the u.s. government , we would likely curtail certain infectious disease research and development efforts , though we may pursue additional cash resources through public or private financings , seek additional government contracts and establish collaborations with or license our technology to other companies . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with government sponsored programs and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenue or profitable operations . summary and timeline of eteplirsen data disclosure in october 2010 , we announced results from a clinical trial of eteplirsen ( “ avi study 28 ” ) . data from this study were published in the lancet in july 2011. avi study 28 was a phase ib/iia open label , dose-ranging , clinical trial assessing the safety , tolerability , pharmacokinetics and exploratory efficacy of eteplirsen in ambulatory individuals with dmd . participants in avi study 28 were between the ages of five and 15 with errors in the gene coding for dystrophin , which were amenable to treatment by skipping exon 51. participants were dosed once per week for 12 weeks . a total of 19 participants were enrolled and these individuals were assigned to one of six dose cohorts of 0.5 , 1.0 , 2.0 , 4.0 , 10.0 or 20.0 mg/kg . of the 19 participants enrolled , 18 received at least ten of the 12 doses planned in this trial . after completion of dosing , participants were followed for an additional 14 weeks . muscle biopsies were taken before treatment and 17 participants had a second biopsy at week 14 , two weeks after administration of the final dose . the primary objective of the trial was to assess the safety of eteplirsen at these doses over the 26-week duration of the trial . secondary trial objectives included assessment of plasma pharmacokinetics , urinary elimination and exploratory endpoints evaluating biological activity and clinical performance . this trial was conducted by investigators in the united kingdom at the university college london institute of child health / great ormond street hospital in london and at the royal victoria infirmary in newcastle-upon-tyne . story_separator_special_tag these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from b aseline through week 144 in the itt population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , showed a 14.7 percent mean increase in mip and a 12.8 percent mean increase in mep . analyses of mip percent predicted ( mip adju sted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 93.9 percent at week 144 in mip percent predicted , and a mean change from 79.3 percent at baseline to 75.7 percent at week 144 in mep percent predicted . in addition , there was a mean increase in forced vital capacity ( “ fvc ” ) , a measure of lung volume , of 11.0 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 144 , with 1 01.3 percent at baseline and 90.9 percent at week 144. through 144 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there w ere no treatment-related hospitalizations or discontinuations . in january 2015 , we announced that at week 168 , the six patients in the mitt population in the 30 and 50 mg/kg eteplirsen cohorts who were able to perform the 6mwt experienced a decline of 76.7 meters , or about 19.5 percent , from baseline in walking ability . a statistically significant treatment benefit of 65.4 meters ( p < 0.017 ) was observed compared with the placebo/delayed-treatment cohort ( n=4 ) , which initiated treatment at week 25 following 24 weeks of placebo . this cohort , after experiencing a substantial decline of 68.4 meters from baseline to week 36 , demonstrated a decline of 73 meters in walking ability from week 36 through week 168 , the period from which meaningful levels of dystrophin were likely produced . these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from baseline through week 168 in the intent-to-treat population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , continued to show a 11.1 percent mean increase in mip and a 14.7 percent mean increase in mep . analyses of mip percent predicted ( mip adjusted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 89.5 percent at week 168 in mip percent predicted , and a mean change from 79.3 percent at baseline to 74.3 percent at week 168 in mep percent predicted . in addition , there was a mean increase in fvc , a measure of lung volume , of 11.6 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 168 , with 101.3 percent at baseline and 91.9 percent at week 168. through 168 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . in october 2015 , we announced additional clinical efficacy and safety data that demonstrated that ( i ) eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk ( as measured by the 6mwt ) at three years , compared with external controls , ( ii ) the fourth biopsy data confirmed the mechanism of action of eteplirsen , demonstrating exon skipping in all patients and dystrophin production in nearly all patients and ( iii ) at three years , the safety data remained consistent with prior results . in january 2016 , the fda made public our eteplirsen briefing document addendum ( the “ january 2016 addendum ” ) which disclosed that at four years , 10 out of 12 patients on eteplirsen remained ambulatory while 10 out of 13 untreated patients in the external control had lost ambulation ( one patient in the external control was still ambulatory at year 4 , while 2 patients in the external control were missing data at 4 years ) , a statistically significant difference . in addition , the january 2016 addendum disclosed a statistically significant advantage of 162 meters in the ability of study participants to walk ( as measured by the 6mwt ) at four years . key financial metrics revenue government research contract and grant revenue . in the periods presented in this report , substantially all of our revenues were derived from research and development contracts with and grants from the u.s. government . we recognize revenue from u.s. government research contracts and grants during the period in which the related expenses are incurred and present such revenues and related expenses on a gross basis in the consolidated financial statements . our government contracts are subject to government audits , which may result in catch-up adjustments . as of december 31 , 2014 , we had completed all development activities of our contracts with the u.s. government . the majority of the revenue under our u.s. government contracts was recognized as of december 31 , 2015 and only revenue for contract finalization , if any , is expected in the future . if a technology , right , product or service is separate and independent of our performance under other elements of an arrangement , we defer recognition of non-refundable up-front fees if we have continuing performance obligations when the technology , right , product or service conveyed in conjunction with the non-refundable fee has no utility to the

